Table 1 Basic clinical characteristics and clinical outcomes of the whole cohort.

From: Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group

Characteristic

Whole cohort n = 292

KMT2A::MLLT3 n = 96

KMT2A::AFDN n = 69

KMT2A::ELL n = 61

KMT2A::MLLT10 n = 34

KMT2A::MLLT1 n = 13

Other KMT2A-r n = 19

P value

Age, years (range)

40.0 (15.0–72.0)

37.5 (15.0–68.0)

41.0 (15.0–70.0)

42.0 (15.0–69.0)

38.5 (16.0–72.0)

46.0 (17.0–65.0)

41.0 (28.0–67.0)

0.706

Age group, n (%)

 Younger (<60 y)

261 (89.4)

86 (89.6)

62 (89.9)

55 (90.2)

31 (91.2)

12 (92.3)

15 (78.9)

0.805

 Older (≥60 y)

31 (10.6)

10 (10.4)

7 (10.1)

6 (9.8)

3 (8.8)

1 (7.7)

4 (21.1)

 

Sex, n (%)

 Male

133 (45.5)

42 (43.75)

34 (49.3)

26 (42.6)

19 (55.9)

6 (46.2)

6 (31.6)

0.596

 Female

159 (54.5)

54 (56.25)

35 (50.7)

35 (57.4)

15 (44.1)

7 (53.8)

13 (68.4)

 

WBC count, ×109/L (range)

14.2 (0.3–398.0)

4.7 (0.3–315.7)

55.2 (0.8–398.0)

17.6 (1.2–248.0)

6.1 (0.8–142.5)

3.5 (0.9–311.2)

8.8 (0.7–156.0)

<0.001c

WBC group, n (%)

 Low (<100)

245 (83.9)

81 (84.4)

48 (69.6)

56 (91.8)

33 (97.1)

11 (84.6)

16 (84.2)

0.003d

 High (≥100)

47 (16.1)

15 (15.6)

21 (30.4)

5 (8.2)

1 (2.9)

2 (15.4)

3 (15.8)

 

Gene mutationsa, n (%)

N = 271

N = 87

N = 64

N = 58

N = 32

N = 12

N = 18

 

 KRAS mutations

45 (16.6)

14 (16.1)

13 (20.3)

12 (20.7)

2 (6.3)

1 (8.3)

3 (16.7)

0.490

 NRAS mutations

41 (15.1)

14 (16.1)

5 (7.8)

11 (19.0)

5 (15.6)

2 (16.7)

4 (22.2)

0.432

 FLT3-ITD mutations

23 (8.5)

4 (4.6)

6 (9.4)

11 (19.0)

1 (3.1)

1 (8.3)

0 (0.0)

0.040e

 PTPN11 mutations

18 (6.6)

4 (4.6)

3 (4.7)

6 (10.3)

2 (6.3)

0 (0.0)

3 (16.7)

0.336

Courses of induction chemotherapy before CR1, median (range)

1 (1–4)

1 (1–4)

1 (1–4)

1 (1–4)

1 (1–4)

1 (1–3)

1 (1–2)

0.077

Courses of consolidation chemotherapy, median (range)

1 (0–10)

1 (0–6)

1 (0–6)

2 (0–5)

1 (0–4)

2 (0–4)

1 (0–10)

0.511

CR1, n (%)

 NE

18b (6.2)

7 (7.3)

2 (2.9)

4 (6.6)

2 (5.9)

1 (7.7)

2 (10.5)

 

 No

20 (6.8)

6 (6.3)

7 (10.1)

3 (4.9)

3 (8.8)

1 (7.7)

0 (0.0)

0.827

 Yes

254 (87.0)

83 (86.5)

60 (87.0)

54 (88.5)

29 (85.3)

11 (84.6)

17 (89.5)

 

Allo-HSCT in CR1

192 (65.8)

59 (61.5)

48 (69.6)

45 (73.8)

22 (64.7)

5 (38.5)

13 (68.4)

0.121

Outcome, % (95% CI)

 3-year OS

59.4 (53.4–66.0)

57.2 (46.9–69.6)

61.0 (49.1–75.7)

65.3 (53.6–79.6)

59.3 (44.4–79.2)

32.8 (13.3–81.0)

58.6 (38.9–88.4)

0.410

 3-year CIR

32.3 (26.0–38.7)

34.0 (23.4–44.9)

37.1 (22.2–52.0)

21.3 (11.2–33.4)

40.3 (21.6–58.3)

58.8 (10.4–88.3)

13.9 (2.0–37.0)

0.175

  1. AML acute myeloid leukemia, WBC white blood cell, Allo-HSCT allogeneic hematopoietic stem cell transplantation, CR1 first complete remission, NE nonevaluable for response, CI confidence interval, OS overall survival, CIR cumulative incidence of relapse.
  2. aAssessed in available data.
  3. b18 patients were not evaluated, 17 of whom dead without evaluation and 1 of whom not evaluated for personal reason.
  4. cThe adjusted P value by Bonferoni method for AFDN was less than 0.001 compared to MLLT3 and 0.029 compared to MLLT10.
  5. dThe adjusted P value by Bonferoni method for AFDN was 0.024 compared to ELL and 0.021 compared to MLLT10.
  6. eNo statistical differences between groups after further pairwise comparison.
Back to article page